- Home
- ALXO vs MDAI Comparison
ALXO vs MDAI Comparison
Compare ALXO & MDAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALXO
- MDAI
- Stock Information
- Founded
- ALXO 2015
- MDAI 2013
- Country
- ALXO United States
- MDAI United States
- Employees
- ALXO N/A
- MDAI N/A
- Industry
- ALXO Biotechnology: Pharmaceutical Preparations
- MDAI Medical/Dental Instruments
- Sector
- ALXO Health Care
- MDAI Health Care
- Exchange
- ALXO Nasdaq
- MDAI Nasdaq
- Market Cap
- ALXO 56.8M
- MDAI 51.9M
- IPO Year
- ALXO 2020
- MDAI N/A
- Fundamental
- Price
- ALXO $1.05
- MDAI $1.99
- Analyst Decision
- ALXO Strong Buy
- MDAI Strong Buy
- Analyst Count
- ALXO 6
- MDAI 1
- Target Price
- ALXO $3.30
- MDAI $3.50
- AVG Volume (30 Days)
- ALXO 1.7M
- MDAI 275.7K
- Earning Date
- ALXO 11-06-2025
- MDAI 11-05-2025
- Dividend Yield
- ALXO N/A
- MDAI N/A
- EPS Growth
- ALXO N/A
- MDAI N/A
- EPS
- ALXO N/A
- MDAI N/A
- Revenue
- ALXO N/A
- MDAI $27,549,000.00
- Revenue This Year
- ALXO N/A
- MDAI N/A
- Revenue Next Year
- ALXO N/A
- MDAI $60.05
- P/E Ratio
- ALXO N/A
- MDAI N/A
- Revenue Growth
- ALXO N/A
- MDAI 22.27
- 52 Week Low
- ALXO $0.40
- MDAI $0.82
- 52 Week High
- ALXO $2.36
- MDAI $3.25
- Technical
- Relative Strength Index (RSI)
- ALXO 54.14
- MDAI 46.01
- Support Level
- ALXO $1.01
- MDAI $1.78
- Resistance Level
- ALXO $1.27
- MDAI $2.02
- Average True Range (ATR)
- ALXO 0.12
- MDAI 0.11
- MACD
- ALXO -0.02
- MDAI 0.02
- Stochastic Oscillator
- ALXO 29.03
- MDAI 58.33
About ALXO ALX Oncology Holdings Inc.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.
About MDAI Spectral AI Inc.
Spectral AI Inc is an AI company, focused on predictive medical diagnostics. Spectral is devoting substantially all of its efforts towards the research and development of its DeepView System, an internally developed MSI device that has designated FDA BDD status. Its DeepView System uses proprietary algorithms to distinguish between damaged and healthy human tissue invisible to the naked eye, providing Day One healing assessments in seconds. The Company's output is specifically engineered to allow the physician to make a more accurate, timely, and informed decision regarding the treatment of the patient's wound.